Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCT NASDAQ:AUPH NASDAQ:HRTX NASDAQ:SUPN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$3.31+3.4%$3.11$1.05▼$3.97$360M2574,312 shs393,496 shsAUPHAurinia Pharmaceuticals$12.52-2.3%$10.96$6.55▼$12.90$1.69B1.261.43 million shs1.40 million shsHRTXHeron Therapeutics$1.24$1.59$1.04▼$2.68$227.31M1.221.36 million shs1.16 million shsSUPNSupernus Pharmaceuticals$43.99$39.91$29.16▼$46.78$2.47B0.79601,250 shs1.06 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics+3.28%+0.09%+5.41%+9.20%+7.29%AUPHAurinia Pharmaceuticals-2.26%+1.38%+2.04%+58.08%+75.60%HRTXHeron Therapeutics0.00%-4.62%-6.77%-38.00%-32.24%SUPNSupernus Pharmaceuticals0.00%-4.43%+3.05%+33.46%+39.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$3.31+3.4%$3.11$1.05▼$3.97$360M2574,312 shs393,496 shsAUPHAurinia Pharmaceuticals$12.52-2.3%$10.96$6.55▼$12.90$1.69B1.261.43 million shs1.40 million shsHRTXHeron Therapeutics$1.24$1.59$1.04▼$2.68$227.31M1.221.36 million shs1.16 million shsSUPNSupernus Pharmaceuticals$43.99$39.91$29.16▼$46.78$2.47B0.79601,250 shs1.06 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics+3.28%+0.09%+5.41%+9.20%+7.29%AUPHAurinia Pharmaceuticals-2.26%+1.38%+2.04%+58.08%+75.60%HRTXHeron Therapeutics0.00%-4.62%-6.77%-38.00%-32.24%SUPNSupernus Pharmaceuticals0.00%-4.43%+3.05%+33.46%+39.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 3.00Buy$7.75134.14% UpsideAUPHAurinia Pharmaceuticals 3.00Buy$13.003.83% UpsideHRTXHeron Therapeutics 2.33Hold$4.50262.90% UpsideSUPNSupernus Pharmaceuticals 2.50Moderate Buy$43.00-2.25% DownsideCurrent Analyst Ratings BreakdownLatest HRTX, SUPN, ADCT, and AUPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/29/2025SUPNSupernus PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$36.00 ➝ $40.008/19/2025SUPNSupernus PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/13/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/12/2025HRTXHeron TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell8/8/2025HRTXHeron TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $3.008/6/2025SUPNSupernus PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$42.00 ➝ $46.008/1/2025AUPHAurinia PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$8.00 ➝ $9.007/30/2025AUPHAurinia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.007/30/2025SUPNSupernus PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight$42.006/20/2025ADCTADC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$8.00 ➝ $5.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$70.84M5.26N/AN/A($2.10) per share-1.58AUPHAurinia Pharmaceuticals$235.13M7.01$0.30 per share41.53$2.68 per share4.67HRTXHeron Therapeutics$144.29M1.58N/AN/A($0.22) per share-5.64SUPNSupernus Pharmaceuticals$661.82M3.73$4.17 per share10.55$18.76 per share2.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$157.85M-$1.57N/AN/AN/A-220.00%N/A-53.73%11/6/2025 (Estimated)AUPHAurinia Pharmaceuticals$5.75M$0.4329.1222.36N/A23.31%20.06%13.81%11/6/2025 (Estimated)HRTXHeron Therapeutics-$13.58M-$0.02N/AN/AN/A-0.62%N/A-0.40%11/11/2025 (Estimated)SUPNSupernus Pharmaceuticals$73.86M$1.1538.2530.55N/A9.70%14.22%10.82%11/3/2025 (Estimated)Latest HRTX, SUPN, ADCT, and AUPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ADCTADC Therapeutics-$0.36-$0.50-$0.14-$0.50$17.82 million$18.84 million8/8/2025Q2 2025HRTXHeron Therapeutics-$0.01-$0.02-$0.01-$0.02$38.08 million$37.20 million7/31/2025Q2 2025AUPHAurinia Pharmaceuticals$0.17$0.16-$0.01$0.16$64.27 million$70.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/AAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/ASUPNSupernus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.934.66AUPHAurinia Pharmaceuticals0.185.234.63HRTXHeron TherapeuticsN/A0.820.53SUPNSupernus PharmaceuticalsN/A2.582.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%AUPHAurinia Pharmaceuticals36.83%HRTXHeron Therapeutics80.01%SUPNSupernus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%AUPHAurinia Pharmaceuticals12.20%HRTXHeron Therapeutics5.86%SUPNSupernus Pharmaceuticals8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics310112.50 million106.42 millionOptionableAUPHAurinia Pharmaceuticals300131.63 million115.57 millionOptionableHRTXHeron Therapeutics300183.32 million172.57 millionOptionableSUPNSupernus Pharmaceuticals58056.07 million51.14 millionOptionableHRTX, SUPN, ADCT, and AUPH HeadlinesRecent News About These CompaniesSupernus Pharmaceuticals (NASDAQ:SUPN) SVP Sells $229,350.00 in StockSeptember 16 at 8:27 PM | marketbeat.com3 Reasons to Avoid SUPN and 1 Stock to Buy InsteadSeptember 16 at 8:47 AM | finance.yahoo.comSupernus Pharmaceuticals (NASDAQ:SUPN) SVP Frank Mottola Sells 5,000 SharesSeptember 16 at 4:50 AM | insidertrades.comRhumbline Advisers Sells 7,121 Shares of Supernus Pharmaceuticals, Inc. $SUPNSeptember 15 at 3:45 AM | marketbeat.comVillanova Investment Management Co LLC Has $641,000 Stock Position in Supernus Pharmaceuticals, Inc. $SUPNSeptember 13, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. $SUPN Shares Sold by Great Lakes Advisors LLCSeptember 12, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) CEO Sells $292,645.38 in StockSeptember 11, 2025 | marketbeat.comAxiom Investors LLC DE Sells 15,521 Shares of Supernus Pharmaceuticals, Inc. $SUPNSeptember 11, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) CEO Jack Khattar Sells 55,578 SharesSeptember 10, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) Hits New 52-Week High - Here's WhySeptember 10, 2025 | marketbeat.comCEO’s Major Stock Sale Shakes Up Supernus PharmaceuticalsSeptember 9, 2025 | tipranks.comCan Mixed Fundamentals Have A Negative Impact on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Current Share Price Momentum?September 9, 2025 | finance.yahoo.comSupernus Pharmaceuticals (NASDAQ:SUPN) CEO Sells $2,557,143.78 in StockSeptember 9, 2025 | insidertrades.comUnpacking Q2 Earnings: Eli Lilly (NYSE:LLY) In The Context Of Other Branded Pharmaceuticals StocksSeptember 8, 2025 | finance.yahoo.comSupernus Pharmaceuticals, Inc. $SUPN Stock Position Cut by PDT Partners LLCSeptember 6, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. $SUPN Stock Position Raised by Cubist Systematic Strategies LLCSeptember 6, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) Hits New 52-Week High - What's Next?September 4, 2025 | marketbeat.comTrexquant Investment LP Has $4.73 Million Holdings in Supernus Pharmaceuticals, Inc. $SUPNSeptember 3, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. $SUPN Shares Purchased by Armistice Capital LLCSeptember 2, 2025 | marketbeat.comNorthern Trust Corp Cuts Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPNSeptember 2, 2025 | marketbeat.com2 Healthcare Stocks on Our Watchlist and 1 We AvoidSeptember 1, 2025 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHRTX, SUPN, ADCT, and AUPH Company DescriptionsADC Therapeutics NYSE:ADCT$3.31 +0.11 (+3.44%) Closing price 09/16/2025 03:59 PM EasternExtended Trading$3.45 +0.14 (+4.20%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Aurinia Pharmaceuticals NASDAQ:AUPH$12.52 -0.29 (-2.26%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$12.52 0.00 (0.00%) As of 07:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Heron Therapeutics NASDAQ:HRTX$1.24 0.00 (0.00%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$1.25 +0.01 (+0.40%) As of 06:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Supernus Pharmaceuticals NASDAQ:SUPN$43.99 0.00 (0.00%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$44.02 +0.02 (+0.06%) As of 06:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
